Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Rapamycin
Cat. No.:
OB0225LY-0235
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC and LC-MS.
Size:
Product Overview
Description:
Rapamycin is a macrolide compound with immunosuppressive and antitumor properties.
Synonym:
Sirolimus; AY 22989; NSC-2260804; 53123-88-9; (-)-Rapamycin; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
CAS No.:
53123-88-9
Compound CID:
5284616
Formula:
C51H79NO13
Formula Weight:
914.17
Specification
Relative Density:
1.182 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Rapamycin can be used as an mTOR inhibitor.
Library Information
Targets:
PIKK family
Receptors:
FKBP; mTOR
Pathways:
PI3K/Akt/mTOR signaling; Metabolism; Autophagy; Microbiology/Virology
Plate Number:
AOCL-3
Plate Location:
h9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
100 mg/mL; 109 mM
Ethanol Max Solubility:
100 mg/mL; 109 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (10.94 mM), insoluble in water.
ALogP:
6.295
HBA_Count:
10
HBD_Count:
2
Rotatable Bond:
6
